Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Liabilities and Shareholders Equity: 2018-2024

Historic Liabilities and Shareholders Equity for Neurogene (NGNE) over the last 4 years, with Dec 2024 value amounting to $335.7 million.

  • Neurogene's Liabilities and Shareholders Equity rose 75.38% to $287.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 62.26%. This contributed to the annual value of $335.7 million for FY2024, which is 50.84% up from last year.
  • Per Neurogene's latest filing, its Liabilities and Shareholders Equity stood at $335.7 million for FY2024, which was up 50.84% from $222.6 million recorded in FY2023.
  • Neurogene's 5-year Liabilities and Shareholders Equity high stood at $335.7 million for FY2024, and its period low was $222.6 million during FY2023.
  • Over the past 2 years, Neurogene's median Liabilities and Shareholders Equity value was $279.2 million (recorded in 2023), while the average stood at $279.2 million.
  • Data for Neurogene's Liabilities and Shareholders Equity shows a peak YoY soared of 50.84% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Neurogene's Liabilities and Shareholders Equity stood at $222.6 million in 2023, then spiked by 50.84% to $335.7 million in 2024.